Quantum BioPharma Ltd. (NASDAQ: QNTM) has announced several corporate actions that demonstrate the company's ongoing financial and strategic management. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, settled outstanding debt of $26,812.50 through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share, as approved by the board on August 12, 2025.
Additionally, the company granted 800 restricted share units each to clinical advisors Peter Stys and Jack Antel under its equity incentive plan on August 15, 2025. These RSUs are specifically tied to regulatory milestones for Quantum BioPharma's Lucid MS program, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Both the creditor shares and RSUs are subject to a four-month-plus-one-day statutory hold under Canadian Securities Exchange policy and are not registered under the U.S. Securities Act.
The company also confirmed that Kevin Malone is no longer serving as an advisor to the board effective August 15, 2025, following termination of his agreement. These developments are significant for investors and the biopharmaceutical industry as they reflect Quantum BioPharma's strategic approach to managing liabilities while incentivizing key personnel through milestone-based compensation tied to critical regulatory achievements.
Quantum BioPharma maintains additional value through its ownership stake in Celly Nutrition Corp., which markets the OTC version of UNBUZZD™. The company retains 25.71% ownership of Celly Nutrition as of June 30, 2024, and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical uses. Further information about the company's developments can be found at https://ibn.fm/QNTM.
